Topics

AMAG’s Explanation For Makena's Failed Confirmatory Trial Faces Skeptical US FDA

17:35 EDT 27 Oct 2019 | SCRIP

Post hoc analyses show no convincing evidence that PROLONG trial's failure to meet its coprimary efficacy endpoints stemmed from baseline...

      

Related Stories

 

Original Article: AMAG’s Explanation For Makena's Failed Confirmatory Trial Faces Skeptical US FDA

NEXT ARTICLE

More From BioPortfolio on "AMAG’s Explanation For Makena's Failed Confirmatory Trial Faces Skeptical US FDA"

Quick Search